Aktis Oncology, Inc. (AKTS) stock

On 1 of our idea list: More cash than they're worth

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Aktis Oncology, Inc. is a clinical-stage biopharmaceutical company that develops targeted radiopharmaceuticals to treat solid tumors. The company utilizes a proprietary miniprotein radioconjugate platform to bind radioisotope payloads, such as alpha-emitting actinium-225, to cancer cells while rapidly clearing normal tissues. Its lead product candidate, [225Ac]Ac-AKY-1189, targets Nectin-4-expressing cancers, including urothelial cancer and other solid tumors such as lung, breast, colorectal, and cervical malignancies. Another candidate in development, [225Ac]Ac-AKY-2519, targets B7-H3-expressing tumors such as prostate and lung cancers. The company also maintains early-stage discovery programs and a research collaboration with Eli Lilly. Its target patients are individuals diagnosed with solid tumor cancers expressing these specific tumor markers.